The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $26.01

Today's change+0.19 +0.74%
Updated December 6 4:03 PM EST. Delayed by at least 15 minutes.
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $26.01

Today's change+0.19 +0.74%
Updated December 6 4:03 PM EST. Delayed by at least 15 minutes.

AstraZeneca PLC up (U.S.)$0.19

AstraZeneca PLC closed up Tuesday by (U.S.)$0.19 or 0.74% to (U.S.)$26.01. Over the last five days, shares have lost 2.62% and sit 1.29% above their 52-week low. This security has underperformed the S&P 500 by 29.08% during the last year.

Key company metrics

  • Open(U.S.) $26.02
  • Previous close(U.S.) $25.82
  • High(U.S.) $26.06
  • Low(U.S.) $25.86
  • Bid / Ask(U.S.) $25.95 / (U.S.) $25.99
  • YTD % change-23.39%
  • Volume5,150,336
  • Average volume (10-day)9,030,354
  • Average volume (1-month)8,157,175
  • Average volume (3-month)6,009,874
  • 52-week range(U.S.) $25.68 to (U.S.) $35.04
  • Beta0.75
  • Trailing P/E26.70×
  • P/E 1 year forward12.50×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $1.40
  • Dividend yield5.38%
  • Trailing EPS(U.S.) $0.97
Updated December 6 4:03 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+10.06%

Based on its net profit margin of 10.06%, AstraZeneca PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.20%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue5,6995,6036,1156,399
Total other revenue--------
Total revenue5,6995,6036,1156,399
Gross profit4,8584,5605,1205,164
Total cost of revenue8411,0439951,235
Total operating expense4,6715,3005,0775,311
Selling / general / administrative1,9682,1912,2032,560
Research & development1,3371,3841,4291,567
Depreciation / amortization297309263360
Interest expense (income), net operating--------
Unusual expense (income)33576526382
Other operating expenses, total-107-392-76-493
Operating income1,0283031,0381,088
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax676-30723802
Income after tax995-31625808
Income tax, total-319198-6
Net income1,014-3646808
Total adjustments to net income--------
Net income before extra. items1,014-3646808
Minority interest1928210
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,014-3646808
Inc. avail. to common incl. extra. items1,014-3646808
Diluted net income1,014-3646808
Dilution adjustment0--00
Diluted weighted average shares1,2661,2651,2651,265
Diluted EPS excluding extraordinary itemsvalue per share0.800.000.510.64
Dividends per sharevalue per share0.000.900.001.90
Diluted normalized EPSvalue per share1.070.590.731.49